The 4thEst8 initiated coverage on OpenCell last year because the startup landed a boatload of grants, then claimed to pivot from 'research tool maker' into a cell and gene therapy company.

Only subscribers get to read this.

Hit SUBSCRIBE for freemium or paid content access.